	Sheet 1 of 1
TY. DOCKET NO.	SERIAL NO.
201487/1070 (KUV-101PCT-US)	09/937,739
APPLICANT AUG U,	5 2002、 _是
Amagai et al.	.
FILING DATE	GROUP ART UNIT
March 30, 2000	1632
	201487/1070 (KUV-101PCT-US) APPLICANT Amagai et al. FILING DATE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
				RECE		
				ILCE	IVED	
_				AUG 0	9 2002	
				TECH CENTE	R 1600/2900	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

//		
Y	1	Amagai et al., "Use of Autoantigen-Knockout Mice in Developing an Active Autoimmune Disease Model for Pemphigus,"
		J. Clin. Invest., 105(5):625-631 (2000)
1	2	Fan et al., "BALB/c Mice Produce Blister-Causing Antibodies Upon Immunization with a Recombinant Human Desmoglein 3 ¹ ,"
/	:	J. Immunol., 163:6228-6235 (1999)
	3	Ono et al., Igaku no Ayumi, pp. 282-284 (1995) (abstract)
A	4	Amagai et al., "Desmoglein 3 (Pemphigus vulgaris Antigen) as a Major Autoimmune Target in Paraneoplastic Pemphigus and
		Its Role in Pathogenesis," J. Invest. Dermatol., 110:482 (1998) (abstract)
EXAMINER		DATE CONSIDERED 2//2 7
ā.		7/1/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				Sheet 17 f 2	
U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO	GIO	SERIAL NO.	<u> </u>	
PATENT AND TRADEMARK OFFICE	201487/1070	No. The last	09/937,739	<u>ଲ</u>	MAY
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	MAY 0 p 200			1
	Amagai et al.	2002		æ. ⇒	င ာ
(use several sheets if necessary)	FILING DATE	PADEMARY OF	GROUP ART U	600/29	2002
(PTO-1449)	March 30, 2000	MATTERIAL	1632	290	
				Ç)	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

8/	1	Koch et al., "Targeted Disruption of the Pemphigus Vulgaris Antigen (Desmoglein 3) Gene in Mice Causes Loss of Keratinocyte				
0		Cell Adhesion with a Phenotype Similar to Pemphigus Vulgaris," J. Cell Biology, 137(5):1091-1102 (1997)				
	2	Juhasz et al., "Development of Pemphigus Vulgaris-Like Lesions in Severe Combined Immunodeficiency Disease Mice				
1		Reconstituted with Lymphocytes from Patients," <u>J. Clin. Invest.</u> , 92:2401-2407 (1993)				
1	3	Stanley, "Cell Adhesion Molecules as Targets of Autoantibodies in Pemphigus and Pemphigoid, Bullous Diseases Due to				
		Defective Epidermal Cell Adhesion," Adv. Immunol., 53:291-325 (1993)				
	4	Goodnow, "Balancing Immunity and Tolerance: Deleting and Tuning Lymphocyte Repertoires," Proc. Natl. Acad. Sci. USA,				
		93:2264-2271 (1996)				
	5	MacDonald, "Mechanisms of Immunological Tolerance," Science, 246:982 (1989)				
	6	Bach et al., "Are There Unique Autoantigens Triggering Autoimmune Diseases?" Immunol. Rev., 164:139-155 (1998)				
	7	Hashimoto et al., "Anti-Cell Surface Pemphigus Autoantibody Stimulates Plasminogen Activator Activity of Human Epidermal				
		Cells," J. Exp. Med., 157:259-272 (1983)				
	8	Anhalt et al., "Induction of Pemphigus in Neonatal Mice by Passive Transfer of IgG From Patients with the Disease,"				
		N. Engl. J. Med., 306:1189-1196 (1982)				
	9	Schulz et al., "Development of CD4 CD8 αβTCR NK1.1 T Lymphocytes," J. Immunol., 157:4379-4389 (1996)				
8	10	Koch et al., "Desmoglein 3 Anchors Telogen Hair in the Follicle," J. Cell Sci., 111:2529-2537 (1998)				
XAMINER		DATE CONSIDERED /				
	(3/11/03				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIAL	NUMBER	DATE	NAME	CLASS	SUBCLASS	DATE IF APPRO-
						PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

\mathcal{O}				
X	11	Schiltz et al., "Production of Epidermal Acantholysis in Normal Human Skin In Vitro by the IgG Fraction From Pemphigus		
		Serum," J. Invest. Dermatol., 67:254-260 (1976)		
)	12	Ishii et al., "Characterization of Autoantibodies in Pemphigus Using Antigen-Specific Enzyme-Linked Immunosorbent Assays		
/		With Baculovirus-Expressed Recombinant Desmogleins," J. Immunol., 159:2010-2017 (1997)		
	13	Amagai et al., "Antigen-Specific Immunoadsorption of Pathogenic Autoantibodies in Pemphigus Foliaceus," J. Invest. Dermatol.,		
		104:895-901 (1995)		
	14	Amagai, "Pemphigus: Autoimmunity to Epidermal Cell Adhesion Molecules," Adv. Dermatol., 11:319-352 (1996)		
	15	Amagai et al., "Autoantibodies Against a Novel Epithelial Cadherin in Pemphigus Vulgaris, a Disease of Cell Adhesion,"		
	i	<u>Cell</u> , 67:869-877 (1991)		
	16	Amagai et al., "Antibodies Against Desmoglein 3 (Pemphigus Vulgaris Antigen) Are Present in Sera from Patients With		
		Paraneoplastic Pemphigus and Cause Acantholysis In Vivo in Neonatal Mice," J. Clin. Invest., 102:775-782 (1998)		
	17	Amagai et al., "Usefulness of Enzyme-Linked Immunosorbent Assay Using Recombinant Desmogleins 1 and 3 for Serodiagnosis		
		of Pemphigus," <u>Br. J. Dermatol.</u> , 140:351-357 (1999)		
	18	Dry, "The Coat of the Mouse (Mus musculus)," in Bateson, eds., Journal of Genetics, Vol. XVI. (1926), London: Wm. Dawson &		
		Sons Ltd., pp. 287-340 (reprinted 1963)		
	19	Amagai et al., "Absorption of Pathogenic Autoantibodies by the Extracellular Domain of Pemphigus Vulgaris Antigen (Dsg3)		
		Produced by Baculovirus," J. Clin. Invest., 94:59-67 (1994)		
	20	Amagai et al., "Autoantibodies Against the Amino-Terminal Cadherin-Like Binding Domain of Pemphigus Vulgaris Antigen		
X		are Pathogenic," J. Clin. Invest., 90:919-926 (1992)		
EXAMINER		218 Jil. DATE CONSIDERED 3/11/03		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.